<?xml version="1.0" encoding="UTF-8"?>
<p>Nowadays, there is an increasing attention in exploring potential therapeutic bioactive to treat serious ailments caused by multidrug-resistant bacteria such as chronic wound [
 <xref rid="B3" ref-type="bibr">3</xref>, 
 <xref rid="B4" ref-type="bibr">4</xref>, 
 <xref rid="B8" ref-type="bibr">8</xref>, 
 <xref rid="B9" ref-type="bibr">9</xref>]. WHO reported that there were more than 8.2 million people infected with wounds with or without infection. This caused $28.1–96.8 billion lost to treat acute and chronic wounds. In this regard, the United States lost $25 billion per year for healthcare expenditure for nonhealing ulcer [
 <xref rid="B10" ref-type="bibr">10</xref>]. Likewise, a study conducted in Europe showed that there were 1·5–2 million people agonized from wounds. Unless and otherwise invented for new novel treatment, it imposed serious economic impact and costs $15–22 billion per year in coming five years. It has become major public health problem that caused psycho-social consequence on infected patients [
 <xref rid="B9" ref-type="bibr">9</xref>, 
 <xref rid="B10" ref-type="bibr">10</xref>]. Emerging of MRSA, VRE, and ESBL producing 
 <italic>P. aeruginosa</italic> that identified as common wound colonized MDR bacteria has been worsen medical-surgical care and other health services [
 <xref rid="B9" ref-type="bibr">9</xref>–
 <xref rid="B11" ref-type="bibr">11</xref>]. In such case, essential oils of medicinal plants origin are suitable candidates to develop topical ointments for wound care and beyond [
 <xref rid="B8" ref-type="bibr">8</xref>, 
 <xref rid="B12" ref-type="bibr">12</xref>].
</p>
